Product Details
| Alternative Name: | Probable ubiquitin carboxyl-terminal hydrolase CYLD |
| |
| Host: | Rabbit |
| |
| Immunogen: | Synthetic peptide corresponding to aa 336-353 of human CYLD. |
| |
| UniProt ID: | Q9NQC7 |
| |
| Source: | Purified from rabbit serum. |
| |
| Species reactivity: | Human
|
| |
| Applications: | WB
|
| |
| Recommended Dilutions/Conditions: | Western Blot (1:1,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Purity Detail: | Purified by salt precipitation. |
| |
| Formulation: | Liquid. In PBS containing 0.01% sodium azide. |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored at -20°C. Dilute with PBS, pH 7.2-7.4, containing 1% normal goat serum (if a goat anti-rabbit IgG linker antibody is to be used). Store diluted antibody at +4°C, do not freeze and use within 1 month. |
| |
| Handling: | Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | -20°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | The tumor suppressor CYLD is a deubiquitinylating enzyme (DUB) that antagonises NF-κB and JNK signaling by disassembly of Lys63-linked ubiquitin chains synthesised in response to cytokine stimulation. The DUB activity of CYLD is mediated by its C-terminal ubiquitin specific protease (USP) domain, pathogenic truncations and mutations of which are associated with the hypertrophic skin tumor cylindromatosis through disruption of the USP domain and subsequent loss of CYLD catalytic activity. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Figure: Detection of CYLD in HeLa S100 cytosolic fraction (Prod. No. BML-SW8750, 10µg) by Western blotting using PAb to CYLD (human) (Prod. No. BML-PW0760) at 1:5000 dilution.
Please mouse over
Product Literature References
TRAF-interacting protein (TRIP) negatively regulates the TNF receptor-associated factor 2 (TRAF2) ubiquitin-dependent pathway by suppressing the TRAF2 - sphingosine-1-phosphate (S1P) interaction: E.S. Park, et al.; J. Biol. Chem.
290, 9660 (2015),
Abstract;
Full Text
General Literature References
Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains: D. Komander, et al.; EMBO Rep.
10, 466 (2009),
Abstract;
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module: D. Komander, et al.; Mol. Cell
29, 451 (2008),
Abstract;
Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells: W. Jin, et al.; J. Biol. Chem.
282, 15884 (2007),
Abstract;
Full Text
CYLD in ubiquitin signaling and tumor pathogenesis: F. Ikeda & I. Dikic; Cell
125, 643 (2006),
Abstract;
CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members: E. Trompouki, et al.; Nature
424, 793 (2003),
Abstract;
Identification of the familial cylindromatosis tumour-suppressor gene: G.R. Bignell, et al.; Nat. Genet.
25, 160 (2000),
Abstract;
